AskGene Limited, a Camarillo, CA- and Nanjing, China-based clinical-stage biopharmaceutical company focusing on the discovery and development of innovative biological drugs, closed a USD 20m Series A financing.
Qiming Venture Partners was the lead and TF Capital was the co-investor.
Proceeds from the financing will be used to advance clinical development of its pipeline of innovative therapeutic candidates and the development of SmartKine® cytokine prodrug platform.
AskGene’s Chief Executive Officer Jeff Lu is leading the development of immunotherapies for cancers. Through its SmartKine® platform technology and pipeline programs, the company aims to achieve its objective of modulating the immune system at a disease site with selectivity and precision. ASKB589 is an anti-CLDN 18.2 antibody in phase I/II and ASKG712 is an anti-VEGF anti-ANG2 antagonist peptide fusion molecule.